Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
EVEROLIMUS 10 mg/stuk
Sandoz B.V. Veluwezoom 22 1327 AH ALMERE
L01XE10
EVEROLIMUS 10 mg/stuk
Tablet
BUTYLHYDROXYTOLUEEN (E 321) ; CROSPOVIDON (E 1202) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; LACTOSE 0-WATER ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b)
Oraal gebruik
Everolimus
2019-03-15
Sandoz B.V. Page 1/10 Everolimus Sandoz ® 2,5, 5, 10 mg, tabletten RVG 122426, 122427, 122428 1311-v7 1.3.1.1 Bijsluiter Mei 2022 BIJSLUITER: INFORMATIE VOOR DE PATIËNT EVEROLIMUS SANDOZ ® 2,5 MG, TABLETTEN EVEROLIMUS SANDOZ ® 5 MG, TABLETTEN EVEROLIMUS SANDOZ ® 10 MG, TABLETTEN everolimus _ _ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What [Nationally completed name] is and what it is used for 2. What you need to know before you take [Nationally completed name] 3. How to take [Nationally completed name] 4. Possible side effects 5. How to store [Nationally completed name] 6. Contents of the pack and other information 1. WHAT [NATIONALLY COMPLETED NAME] IS AND WHAT IT IS USED FOR _ _ [Nationally completed name] is an anticancer medicine containing the active substance everolimus. Everolimus reduces the blood supply to the tumour and slows down the growth and spread of cancer cells. [Nationally completed name] is used to treat adult patients with: • hormone receptor-positive advanced breast cancer in postmenopausal women, in whom other treatments (so called “non-steroidal aromatase inhibitors”) no longer keep the disease under control. It is given together with a medicine called exemestane, a steroidal aromatase inhibitor, which is used for hormonal anticancer therapy. • advanced tumours called neuroendocrine tumours that originate from the stomach, bowels, lung or pancreas. It is given if the tumours are inoperable and do not overproduce specific hormones or other related natural sub Lees het volledige document
Sandoz B.V. Page 1/32 Everolimus Sandoz 2,5, 5, 10 mg, tabletten RVG 122426, 122427, 122428 1311-v9 1.3.1.1 Samenvatting van de Productkenmerken Mei 2023 1. NAAM VAN HET GENEESMIDDEL Everolimus Sandoz 2,5 mg, tabletten Everolimus Sandoz 5 mg, tabletten Everolimus Sandoz 10 mg, tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION [NATIONALLY COMPLETED NAME] 2.5 MG TABLETS Each tablet contains 2.5 mg of everolimus. Excipient with known effect Each tablet contains 74.2 mg of lactose. [NATIONALLY COMPLETED NAME] 5 MG TABLETS Each tablet contains 5 mg of everolimus _. _ _ _ Excipient with known effect Each tablet contains 148.4 mg of lactose. [NATIONALLY COMPLETED NAME] 10 MG TABLETS Each tablet contains 10 mg of everolimus. Excipient with known effect Each tablet contains 296.8 mg of lactose. For the full list of excipients, see section 6.1. _ _ 3. PHARMACEUTICAL FORM Tablet. [NATIONALLY COMPLETED NAME] 2.5 MG TABLETS White to slightly yellow, elongated tablets approximately 10.1 x 4.1 mm with a bevelled edge and no score, engraved with “LCL” on one side and “NVR” on the other. [NATIONALLY COMPLETED NAME] 5 MG TABLETS White to slightly yellow, elongated tablets approximately 12.1 x 4.9 mm with a bevelled edge and no score, engraved with “5” on one side and “NVR” on the other. [NATIONALLY COMPLETED NAME] 10 MG TABLETS Sandoz B.V. Page 2/32 Everolimus Sandoz 2,5, 5, 10 mg, tabletten RVG 122426, 122427, 122428 1311-v9 1.3.1.1 Samenvatting van de Productkenmerken Mei 2023 White to slightly yellow, elongated tablets approximately 15.1 x 6.0 mm with a bevelled edge and no score, engraved with “UHE” on one side and “NVR” on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hormone receptor-positive advanced breast cancer [Nationally completed name] is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a no Lees het volledige document